Skip to main content
. 2023 Oct 24;97:104846. doi: 10.1016/j.ebiom.2023.104846

Fig. 5.

Fig. 5

The transcriptomic heterogeneities of malignant cells in CSCC and CAde. (a–b) t-SNE plots of malign epithelial cells, colored by cell clusters and individual samples, respectively. (c) Dot plots revealed the gene expression profiles of each malignant cell cluster. (d) Heatmap revealed the molecular functions of each malignant cell cluster based on GSVA analysis (MSigDB_C6). (e) The box plot depicted the stemness score of malignant cells in CSCC and CAde. The P-value was calculated by Wilcoxon Rank Sum Test. (f) Forest plot of the identified differentially expressed genes from snRNA-seq data for CSCC and CAde regarding overall survival. (g) Representative IHC staining of MTSS1 in collected CSCC (n = 32) and CAde (n = 11) samples. ∗∗∗P < 0.001. The P-value was calculated by Wilcoxon Rank Sum Test. (h) Representative IHC staining of POLA1 in collected CSCC (n = 32) and CAde (n = 11) samples. ∗∗∗P < 0.001. The P-value was calculated by Wilcoxon Rank Sum Test. (i) The ROC curve (sensitivity against 1-specificity) of identified specific gene signature for classifying CSCC and CAde based on TCGA CESC cohort. (j) Dot plots displayed the abnormally activated transcription factors (TFs) for CSCC and CAde. (k) Radar plot displayed the expression profiles of identified TFs in CC cell lines. The distance from the dots to the center of the circle represented the log2 (relative gene expression). (l) Gene regulatory network among TFs and target genes in malignant epithelial cells. Significant genes meant the adjusted P-value <0.01 and |Log2FC| > 0.25. P-value was calculated by Wilcoxon Rank Sum t-test. (m) Scatter plots of switch point of a certain drugs in CSCC and CAde. The switch point of certain drug less than 0.1 was defined as sensitivity, and the sensitivity of drugs in CSCC and CAde were denoted by color. The Switch Point value of 0 was converted to 0.009 for plotting. (n) IC50 values of selected drugs (Pyrimethamine, Lapatinib, Dasatinib and Doramapimod) in CaSki and HeLa cell line. Each drug had at least three biological replicates in each cell line. (o) Morphological changes of constructed organoids from CSCC and CAde samples after being treated with Lapatinib and Dasatinib. (p) IC50 values of selected drugs (Pyrimethamine, Lapatinib, Dasatinib and Doramapimod) in CSCC- and CAde organoids. Each drug had at least three biological replicates in each constructed organoid.